"It’s exciting to work with world class collaborators here at Genentech as we pursue challenging basic science questions and try to develop innovative treatments for patients in need."
My long-term interest in peptide research started during my graduate training in the Department of Chemistry at NYU, where I developed peptide-mimetic inhibitors of protein-protein interactions and studied alpha-helical peptide folding. I then did a postdoc in the Chemical Biology Laboratory of the US National Cancer Institute to develop peptide-based biomaterials that improve drug delivery and cellular permeability. I joined Genentech at the end of 2020 and am currently a Senior Scientist in the Department of Peptide Therapeutics (Early Discovery Biochemistry). Here, my group is interested in all aspects within the discovery, development, and delivery of next generation peptide drugs.
J. Am. Chem. Soc. 2020, 142, 19950-19955.
My group conducts multidisciplinary research, utilizing a broad range of techniques that include protein engineering, biochemical and biophysical analyses, molecular and cell biology, medicinal chemistry, and bioconjugation. This allows us to actively participate in various stages of early discovery efforts to identify hit peptide molecules from library screening studies, validate synthetically made compounds for binding and cell activity, and optimize drug properties through re-screening efforts, structure-based rational design, and other chemical methods.
Our current research efforts are focused on the development of peptide therapeutics for tissue regeneration, inflammatory bowel disease, pulmonary fibrosis, cancer, and neurodegeneration. To push this work forward, we have ongoing collaborations with colleagues within Peptide Therapeutics and Early Discovery Biochemistry, as well as those in Immunology Discovery, Molecular Oncology, Protein Chemistry, Neuroscience, and Structural Biology.